Chidamide, a Histone Deacetylase Inhibitor, Combined With R‐GemOx in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma (TRUST): A Multicenter, Single‐Arm, Phase 2 Trial

Chidamide, a Histone Deacetylase Inhibitor, Combined With R‐GemOx in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma (TRUST): A Multicenter, Single‐Arm, Phase 2 Trial

ABSTRACT Background Histone deacetylase (HDAC) inhibitors demonstrated a synergistic anti‐tumor effect with rituximab and chemotherapy in preclinical studies on diffuse large B‐cell lymphoma (DLBCL). This phase 2 trial aimed to evaluate the efficacy and safety of chidamide, an orally active HDAC inh...

Full description

Saved in:
Bibliographic Details
Main Authors: Qihua Zou, Yuchen Zhang, Hui Zhou, Yulin Lai, Yi Cao, Zhiming Li, Ning Su, Wenyu Li, Huiqiang Huang, Panpan Liu, Xu Ye, Yudan Wu, Huo Tan, Runhui Zheng, Bingyi Wu, Hui Yang, Liye Zhong, Yuhong Lu, Yang Liang, Peng Sun, Lirong Li, Yingxian Liu, Danling Dai, Yi Xia, Qingqing Cai
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Cancer Medicine
Subjects:
chidamide
diffuse large B‐cell lymphoma
refractory or relapsed
R‐GemOx
transplantation‐ineligible
Online Access:https://doi.org/10.1002/cam4.70919
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items